Phaseline

Companies › Takara Bio

Takara Bio: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology; next expected readout Mar 2032.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TBI-1301
NY-ESO-1 directed CAR-T cell therapy
NY-ESO-1Phase 3Synovial Sarcomas; NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive PatientsMar 2032
TBI-1401(HF10)
Oncolytic herpes simplex virus-1 (HSV-1)
–Phase 1Pancreatic Cancer Stage IIIMar 2035
TBI-1501
anti-CD19 chimeric antigen receptor (CAR)-T cell therapy
CD19Phase 1Lymphoblastic Leukemia, Acute AdultMar 2035

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02869217TBI-1301Phase 1NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive PatientsOncologyNov 2026
NCT07174427TBI-1301Phase 3Synovial SarcomasOncologyMar 2032
NCT03252808TBI-1401(HF10)Phase 1Pancreatic Cancer Stage IIIOncologyMar 2035
NCT03155191TBI-1501Phase 1Lymphoblastic Leukemia, Acute AdultOncologyMar 2035

Targets

NY-ESO-1 (1) CD19 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Companies built like this

Immatics US Allogene Therapeutics Lyell Immunopharma Tesaro Vyriad

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.